Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Cited In for PubMed (Select 13820968)

1.

Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene.

Knowles JW, Xie W, Zhang Z, Chennemsetty I, Assimes TL, Paananen J, Hansson O, Pankow J, Goodarzi MO, Carcamo-Orive I, Morris AP, Chen YD, Mäkinen VP, Ganna A, Mahajan A, Guo X, Abbasi F, Greenawalt DM, Lum P, Molony C, Lind L, Lindgren C, Raffel LJ, Tsao PS; RISC (Relationship between Insulin Sensitivity and Cardiovascular Disease) Consortium; EUGENE2 (European Network on Functional Genomics of Type 2 Diabetes) Study; GUARDIAN (Genetics UndeRlying DIAbetes in HispaNics) Consortium; SAPPHIRe (Stanford Asian and Pacific Program for Hypertension and Insulin Resistance) Study, Schadt EE, Rotter JI, Sinaiko A, Reaven G, Yang X, Hsiung CA, Groop L, Cordell HJ, Laakso M, Hao K, Ingelsson E, Frayling TM, Weedon MN, Walker M, Quertermous T.

J Clin Invest. 2015 Apr;125(4):1739-51. doi: 10.1172/JCI74692. Epub 2015 Mar 23.

2.

Improved drug therapy: triangulating phenomics with genomics and metabolomics.

Monte AA, Brocker C, Nebert DW, Gonzalez FJ, Thompson DC, Vasiliou V.

Hum Genomics. 2014 Sep 1;8:16. doi: 10.1186/s40246-014-0016-9.

3.

Pharmacogenomics and adverse drug reactions in children.

Rieder MJ, Carleton B.

Front Genet. 2014 Apr 16;5:78. doi: 10.3389/fgene.2014.00078. eCollection 2014. Review.

4.
5.

Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Bekker A, Schaaf HS, Seifart HI, Draper HR, Werely CJ, Cotton MF, Hesseling AC.

Antimicrob Agents Chemother. 2014;58(4):2229-34. doi: 10.1128/AAC.01532-13. Epub 2014 Feb 3.

6.

Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Sim E, Abuhammad A, Ryan A.

Br J Pharmacol. 2014 Jun;171(11):2705-25. doi: 10.1111/bph.12598. Review.

7.

Antituberculosis Drug-Induced Hepatotoxicity in IranianTuberculosis Patients: Role of Isoniazid Metabolic Polymorphism.

Sistanizad M, Azizi E, Khalili H, Hajiabdolbaghi M, Gholami K, Mahjub R.

Iran J Pharm Res. 2011 Summer;10(3):633-9.

8.

Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice.

Monte AA, Vasiliou V, Heard KJ.

J Pharmacogenomics Pharmacoproteomics. 2012 Mar 16;S5. pii: 001.

9.

Role of pharmacogenomics in the treatment of tuberculosis: a review.

Ramachandran G, Swaminathan S.

Pharmgenomics Pers Med. 2012;5:89-98. doi: 10.2147/PGPM.S15454. Epub 2012 Sep 13.

10.

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T, Kamimura S, Fujio Y, Kawase I; Pharmacogenetics-based tuberculosis therapy research group.

Eur J Clin Pharmacol. 2013 May;69(5):1091-101. doi: 10.1007/s00228-012-1429-9. Epub 2012 Nov 14.

11.

The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype.

Ruiz JD, Martínez C, Anderson K, Gross M, Lang NP, García-Martín E, Agúndez JA.

PLoS One. 2012;7(9):e44629. doi: 10.1371/journal.pone.0044629. Epub 2012 Sep 6.

12.

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Pasipanodya JG, Srivastava S, Gumbo T.

Clin Infect Dis. 2012 Jul;55(2):169-77. doi: 10.1093/cid/cis353. Epub 2012 Mar 30.

13.

Pharmacogenetics: implementing personalized medicine.

Mini E, Nobili S.

Clin Cases Miner Bone Metab. 2009 Jan;6(1):17-24.

15.

Phenelzine in urine: assay and relation to acetylator status.

Caddy B, Tilstone WJ, Johnstone EC.

Br J Clin Pharmacol. 1976 Aug;3(4):633-7.

16.

Prediction of drug response and safety in clinical practice.

Monte AA, Heard KJ, Vasiliou V.

J Med Toxicol. 2012 Mar;8(1):43-51. doi: 10.1007/s13181-011-0198-7.

17.

Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.

Hein DW, Doll MA.

Pharmacogenomics. 2012 Jan;13(1):31-41. doi: 10.2217/pgs.11.122. Epub 2011 Nov 17.

18.

Pharmacogenetics in Ghana: reviewing the evidence.

Kudzi W, Adjei GO, Ofori-Adjei D, Dodoo AN.

Ghana Med J. 2011 Jun;45(2):73-80.

19.

Cancer pharmacogenomics.

Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE.

Clin Pharmacol Ther. 2011 Sep;90(3):461-6. doi: 10.1038/clpt.2011.126. Epub 2011 Jul 27. Review. No abstract available. Erratum in: Clin Pharmacol Ther. 2011 Dec;90(6):893.

20.

Pharmacogenomics: the genetics of variable drug responses.

Roden DM, Wilke RA, Kroemer HK, Stein CM.

Circulation. 2011 Apr 19;123(15):1661-70. doi: 10.1161/CIRCULATIONAHA.109.914820. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk